^
    Back
    Association details:
    Biomarker:LAG3 overexpression
    Cancer:Melanoma
    Drug Class:PD1 inhibitor +
    LAG-3 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Oncoimmunology
    Title:

    Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

    Published date:
    10/04/2023
    Excerpt:
    LAG-3 expression was significantly higher in responders to anti-PD-1 + anti-LAG-3 combination immunotherapy compared to non-responders (P = .0210; median = 1.0% in responders vs 0.25% in non-responders). The response rate was 84% (n = 27/32) in patients with LAG-3-positive tumors compared to 48% (n = 10/21) in patients with LAG-3-negative tumors....Next, we evaluated the association between LAG-3 expression, PFS and OS. Patients with LAG-3-positive tumors had a significantly longer PFS compared to patients with LAG-3-negative tumors (P = .0037)....In the current study, we demonstrated a significant association between LAG-3 expression and response to combination anti-LAG-3 + anti-PD-1 immunotherapy.
    DOI:
    https://doi.org/10.1080/2162402X.2023.2261248